Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis

Cell Death and Disease

Volumn 4, Issue 9, 2013, Pages

  Steinhart, L ^a   Belz, K ^a   Fulda, S ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Apoptosis; Leukemia; Necroptosis; RIP1; Smac

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BV 6; CASPASE; CASPASE INHIBITOR; MIXED LINEAGE KINASE; PEPTIDOMIMETIC AGENT; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CELL DEATH; DNA FRAGMENTATION; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LEUKEMIA CELL; NECROPTOSIS; PRIORITY JOURNAL;

APOPTOSIS; AUTOCRINE COMMUNICATION; AZACITIDINE; CASPASES; CELL LINE, TUMOR; DNA FRAGMENTATION; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENZYME ACTIVATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; NECROSIS; OLIGOPEPTIDES; PARACRINE COMMUNICATION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84885015530     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.320     Document Type: Article

References (47)

1. Estey E, Dohner H. Acute myeloid leukaemia. Lancet 2006; 368: 1894-1907
2. Schimmer AD. Apoptosis in leukemia: From molecular pathways to targeted therapies. Best Pract Res Clin Haematol 2008; 21: 5-11
3. Fulda S. Cell death in hematological tumors. Apoptosis 2009; 14: 409-423
4. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006; 25: 4798-4811
5. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144: 646-674
6. Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV et al. Molecular definitions of cell death subroutines: Recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ 2012; 19: 107-120
7. Ashkenazi A. Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev 2008; 19: 325-331
8. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007; 87: 99-163
9. Vandenabeele P, Galluzzi L, Vanden Berghe T, Kroemer G. Molecular mechanisms of necroptosis: An ordered cellular explosion. Nat Rev Mol Cell Biol 2010; 11: 700-714
10. Sun L, Wang H, Wang Z, He S, Chen S, Liao D et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell 2012; 148: 213-227
11. Oberst A, Dillon CP, Weinlich R, McCormick LL, Fitzgerald P, Pop C et al. Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis. Nature 2011; 471: 363-367
12. Fulda S, Vucic D, Targeting IAP. proteins for therapeutic intervention in cancer. Nat Rev Drug Discov 2012; 11: 109-124
13. Eckelman BP, Salvesen GS, Scott FL. Human inhibitor of apoptosis proteins: Why XIAP is the black sheep of the family. EMBO Rep 2006; 7: 988-994
14. Bertrand MJ, Milutinovic S, Dickson KM, Ho WC, Boudreault A, Durkin J et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 2008; 30: 689-700
15. Varfolomeev E, Goncharov T, Fedorova AV, Dynek JN, Zobel K, Deshayes K et al. c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NFkappaB activation. J Biol Chem 2008; 283: 24295-24299
16. Tamm I, Kornblau SM, Segall H, Krajewski S, Welsh K, Kitada S et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 2000; 6: 1796-1803
17. Tamm I, Richter S, Scholz F, Schmelz K, Oltersdorf D, Karawajew L et al. XIAP expression correlates with monocytic differentiation in adult de novo AML: Impact on prognosis. Hematol J 2004; 5: 489-495
18. Hess CJ, Berkhof J, Denkers F, Ossenkoppele GJ, Schouten JP, Oudejans JJ et al. Activated intrinsic apoptosis pathway is a key related prognostic parameter in acute myeloid leukemia. J Clin Oncol 2007; 25: 1209-1215
19. Bullinger L, Rucker FG, Kurz S, Du J, Scholl C, Sander S et al. Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia. Blood 2007; 110: 1291-1300
20. Luck SC, Russ AC, Botzenhardt U, Paschka P, Schlenk RF, Dohner H et al. Deregulated apoptosis signaling in core-binding factor leukemia differentiates clinically relevant, molecular marker-independent subgroups. Leukemia 2011; 25: 1728-1738
21. Varfolomeev E, Blankenship JW,Wayson SM, Fedorova AV, Kayagaki N, Garg P et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalphadependent apoptosis. Cell 2007; 131: 669-681
22. Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 2007; 131: 682-693
23. Wang L, Du F, Wang X. TNF-Alpha induces two distinct caspase-8 activation pathways. Cell 2008; 133: 693-703
24. Fakler M, Loeder S, Vogler M, Schneider K, Jeremias I, Debatin KM et al. Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance. Blood 2009; 113: 1710-1722
25. Loeder S, Drensek A, Jeremias I, Debatin KM, Fulda S. Small molecule XIAP inhibitors sensitize childhood acute leukemia cells for CD95-induced apoptosis. Int J Cancer 2010; 126: 2216-2228
26. Loeder S, Fakler M, Schoeneberger H, Cristofanon S, Leibacher J, Vanlangenakker N et al. RIP1 is required for IAP inhibitor-mediated sensitization of childhood acute leukemia cells to chemotherapy-induced apoptosis. Leukemia 2012; 26: 1020-1029
27. Ganetsky A. The role of decitabine for the treatment of acute myeloid leukemia. Ann Pharmacother 2012; 46: 1511-1517
28. Fulda S, Meyer E, Friesen C, Susin SA, Kroemer G, Debatin KM. Cell type specific involvement of death receptor and mitochondri-Al pathways in drug-induced apoptosis. Oncogene 2001; 20: 1063-1075
29. Fulda S, Debatin KM. 5-Aza-2'-deoxycytidine and IFN-gamma cooperate to sensitize for TRAIL-induced apoptosis by upregulating caspase-8. Oncogene 2006; 25: 5125-5133
30. Petersen SL, Wang L, Yalcin-Chin A, Li L, Peyton M, Minna J et al. Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 2007; 12: 445-456
31. Fulda S, Galluzzi L, Kroemer G. Targeting mitochondria for cancer therapy. Nat Rev Drug Discov 2010; 9: 447-464
32. Fulda S. Exploiting inhibitor of apoptosis proteins as therapeutic targets in hematological malignancies. Leukemia 2012; 26: 1155-1165
33. Weisberg E, Kung AL, Wright RD, Moreno D, Catley L, Ray A et al. Potentiation of antileukemic therapies by Smac mimetic, LBW242: Effects on mutant FLT3-expressing cells. Mol Cancer Ther 2007; 6: 1951-1961
34. Weisberg E, Ray A, Barrett R, Nelson E, Christie AL, Porter D et al. Smac mimetics: Implications for enhancement of targeted therapies in leukemia. Leukemia 2010; 24: 2100-2109
35. Carter BZ, Gronda M, Wang Z, Welsh K, Pinilla C, Andreeff M et al. Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells. Blood 2005; 105: 4043-4050
36. Servida F, Lecis D, Scavullo C, Drago C, Seneci P, Carlo-Stella C et al. Novel second mitochondria-derived activator of caspases (Smac) mimetic compounds sensitize human leukemic cell lines to conventional chemotherapeutic drug-induced and death receptormediated apoptosis. Invest New Drugs 2011; 29: 1264-1275
37. Fabre C, Grosjean J, Tailler M, Boehrer S, Ades L, Perfettini JL et al. A novel effect of DNA methyltransferase and histone deacetylase inhibitors: NFkappaB inhibition in malignant myeloblasts. Cell Cycle 2008; 7: 2139-2145
38. Valdez BC, Li Y, Murray D, Corn P, Champlin RE, Andersson BS. 5-Aza-2'-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis. Leuk Res 2010; 34: 364-372
39. Laukens B, Jennewein C, Schenk B, Vanlangenakker N, Schier A, Cristofanon S et al. Smac mimetic bypasses apoptosis resistance in FADD-or caspase-8-deficient cells by priming for tumor necrosis factor alpha-induced necroptosis. Neoplasia 2011; 13: 971-979
40. Vanlangenakker N, Vanden Berghe T, Bogaert P, Laukens B, Zobel K, Deshayes K et al. cIAP1 and TAK1 protect cells from TNF-induced necrosis by preventing RIP1/RIP3-dependent reactive oxygen species production. Cell Death Differ 2011; 18: 656-665
41. Horita H, Frankel AE, Thorburn A. Acute myeloid leukemia-Targeted toxin activates both apoptotic and necroptotic death mechanisms. PLoS One 2008; 3: E3909
42. Marcucci G, Silverman L, Eller M, Lintz L, Beach CL. Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes. J Clin Pharmacol 2005; 45: 597-602
43. Cashen AF, Shah AK, Todt L, Fisher N, DiPersio J. Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Cancer Chemother Pharmacol 2008; 61: 759-766
44. Blum W, Klisovic RB, Hackanson B, Liu Z, Liu S, Devine H et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 2007; 25: 3884-3891
45. Fulda S, Strauss G, Meyer E, Debatin KM. Functional CD95 ligand and CD95 deathinducing signaling complex in activation-induced cell death and doxorubicin-induced apoptosis in leukemic T cells. Blood 2000; 95: 301-308
46. Tchoghandjian A, Jennewein C, Eckhardt I, Rajalingam K, Fulda S. Identification of noncanonical NF-kappaB signaling as a critical mediator of Smac mimetic-stimulated migration and invasion of glioblastoma cells. Cell Death Dis 2013; 4: E564
47. Chou TC. The median-effect principle and the combination index for quantitation of synergism and antagonism. In: Chou TC (eds). Synergism and Antagonism in Chemotherapy. Academic Press: San Diego, USA, 1991. pp 61-102